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Abstract 
We presented data showing that the CART-19 cells expressing the 4-1BB signaling do-
main can have unprecedented and massive in-vivo expansion, traffic to tumor sites, per-
sist long term in vivo, and induce rapid and potent anti-tumor activity in chemotherapy 
refractory CLL patients. 
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Targeted  tumor-specific  cellular  therapy  will 
overcome many of the current limitations of adoptive 
immunotherapy. Gene transfer techniques have now 
been developed to genetically modify T cells to confer 
novel antigen specificity by stably expressing a chi-
meric antigen receptor (CAR) on their surface. CARs 
combine an antigen recognition domain of a specific 
antibody with an intracellular domain of the CD3-zeta 
chain or FcγRI protein into a single chimeric protein 1. 
When antigen is encountered, CAR-modified T cells 
become activated and kill in an antigen dependent, 
but HLA independent manner, making this an attrac-
tive approach as a generalized cancer therapy 2. Until 
recently,  development  of  this  technology  has  been 
limited by lack of efficient T cell culture systems and 
gene transfer techniques. Therefore, most clinical ap-
plications have resulted in limited in vivo expansion 
and persistence of CAR-modified T cells resulting in 
disappointing clinical activity 3,4.  
CD19 is an ideal tumor target. Expression is re-
stricted to B cells, from the pro-B cell stage to mature 
B cells (though not on plasma cells), possibly follicular 
dendritic cells, and it is expressed on the surface of 
most  B  cell  malignancies.  Importantly,  it  is  not  ex-
pressed on pluripotent marrow stem cells 5. 
We have combined a robust T cell culture sys-
tem6 with lentiviral vector transduction of human T 
cells to express a CD19-specific CAR (CART-19 cells). 
The signaling domain of the CAR is critical for activa-
tion of cytolytic activity and survival. First-generation 
CARs typically utilized the intracellular domain of the 
CD3z  chain  only,  the  primary  signaling  molecule 
from endogenous T-cell receptors. Second generation 
CARs had a more potent signaling domain from var-
ious co-stimulatory receptors such as CD28 or CD137 
(4-1BB). Preclinical studies showed that inclusion of 
potent  signaling  molecules  improves  the  antitumor 
activity of genetically modified T cells. Our group has 
tested  a  CAR  directed  against  CD19  linked  to  the 
CD137  (4-1BB)  co-stimulatory  molecule  signaling 
domain  to  enhance  activation  and  signaling  after 
recognition of  CD19. By inclusion of  the 4-1BB sig-
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naling domain, in vitro tumor cell killing, and in-vivo 
anti-tumor activity and persistence of CART-19 cells 
in a murine xenograft model of human ALL is greatly 
enhanced 7. 
Given these preliminary findings, we have initi-
ated a clinical trial to test the feasibility and safety of 
CART-19 cells in patients with CD19+ lymphoid ma-
lignancies. Our initial patients all had advanced, re-
fractory  CLL  (2  with  deletion  of  chromosome  17p) 
and were considered incurable with standard thera-
pies.  All  patients  receive  lymphodepleting  chemo-
therapy 1-4 days prior to CART-19 infusions. Lymph 
node depletion has been necessary for most models of 
adoptive immune therapy. This may permit homeo-
static  proliferation  of  the  infused  T  cells,  eliminate 
competitive T cells that could serve as a “sink” for 
important activating cytokines, result in elimination 
of regulatory and suppressive T cells or even enhance 
endogenous host APC activity 8. 
For manufacturing, CD3+CD45+ cells in a leu-
kapheresis  product  are  positively  selected  with  an-
ti-CD3/anti-CD28 magnetic beads prior to CART-19 
lentiviral vector transduction. After transduction, cells 
are expanded ex-vivo and patients are infused with a 
maximum targeted dose of 5 x 109 total T cells; ap-
proximately 10-30% of cells will express the anti-CD19 
CAR.  
Our preliminary findings were presented at the 
4th Autologous and Allogeneic Cell Therapy in Solid 
Tumors meeting and show that in the initial few pa-
tients, manufacturing was feasible and infusions were 
well tolerated. We presented data showing that the 
CART-19 cells expressing the 4-1BB signaling domain 
can have unprecedented and massive in-vivo expan-
sion, traffic to tumor sites, persist long term in vivo, 
and  induce  rapid  and  potent  anti-tumor  activity  in 
chemotherapy refractory CLL patients. We have not 
observed  clonal  proliferation  of  the  infused  T  cells 
with over 6 months follow-up of treated patients. We, 
and others 4, have observed eradication of B cells and 
hypogammaglobulinemia  in  some  patients  raising 
concern  for  long-term  immune  deficiency,  particu-
larly if the CART-19 cells persist for long periods of 
time. However, to date, no toxicity from B cell defi-
ciency has been noted and repletion of intravenous 
gammaglobulin can be used to minimize risks associ-
ated  with  hypogammaglobulinemia.  The  develop-
ment of a cytokine release syndrome in first patients 
treated highlights the need for caution and continued 
study  of  this  promising  new  therapy.  Treatment  of 
additional patients with detailed analyses and longer 
follow up will be needed to define the ultimate role of 
this therapy.  
The potent activity demonstrated in our first few 
patients is extremely encouraging and suggests that 
autologous  T  cells  genetically  modified  with  redi-
rected specificity for CD19, with the appropriate sig-
naling domain, may offer significant advantages over 
existing  therapies,  including  allogeneic  SCT.  Alt-
hough the clinical application of CAR-modified T cells 
is in its infancy9, there has been remarkable progress 
in  the  last  few  years,  and  we  believe  this  therapy 
holds great promise as a potent and sustained method 
of cancer immunotherapy. 
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